This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Leclercq, G. Articles by Lonsdorfer, M. Search for Related Content PubMed PubMed Citation Articles by Leclercq, G. Articles by Lonsdorfer, M.

Abbott Monoclonal Enzyme Immunoassay Measurement of Estrogen Receptors in Human Breast Cancer: A European Multicenter Study¹

Institut J. Bordet, Bruxelles, Belgium [G. L.]; Institut für Onkologische Biochemie, Dsseldorf, West Germany [H. B.]; Centre Regional François Baclesse, Caen, France [J. G.]; Tenovus Institute for Cancer Research, Cardiff, Wales, United Kingdom [R. I. N.]; Faculté de Médicine de Bicêtre, Bicêtre, France [M-F. P.]; Institute of Radiology, Ferrara, Italy [A. Pi.]; Karolinska Institutet, Huddinge, Sweden [A. Po.]; Finseninstitutet, Kobenhavn, Denmark [S. T.] and Abbott Diagnostic Products GmbH, Wiesbaden, West Germany [M. L.]

A new enzyme immunoassay (Abbott ER-EIA Monoclonal) for the determination of estrogen receptor in cytosols from breast tumor specimens has been developed by Abbott Laboratories. To establish the correlation of the results from this new technique with currently existing steroid binding methods, a multicenter study was conducted in eight European laboratories. All participants followed the same protocol consisting of a familiarization phase, a proficiency evaluation, and a comparison of existing steroid binding methods with the new immunoassay using panel samples and clinical specimens. ER-EIA was compared with the multipoint dextran coated charcoal assay in six laboratories, four of which followed the EORTC⁷ protocol; of the remaining two laboratories, one used a single saturating dose assay, the other an isoelectric focusing assay. The results show no significant difference between reducing agents when used in the ER-EIA. Reproducibility for the immunoassay (interassay coefficient of variation, 6%, interlaboratory coefficient of variation, 11–19%) was somewhat better than that for the steroid binding methods (interlaboratory coefficient of variation, 12–32%). The correlation between the methods was dependent on the origin of the lyophilized specimens. In breast tumor samples, an excellent correlation, (not statistically different from 1) was found between the ER-EIA and the steroid binding method in six laboratories. One laboratory showed a slope of 1.1 for the correlation line; the laboratory using isoelectric focusing showed a slope of 1.9. The mean value determined by the enzyme immunoassay in premenopausal women was 74 fmol/mg cytosol protein, and in postmenopausal women it was 187 fmol/mg cytosol protein with no significant difference in the slope of the correlation line. Results suggest the usefulness of the new standardized enzyme immunoassay for routine use in the clinical laboratory.